Kimærisk antigenreceptor T-cellebehandling til refraktære systemiske autoimmune reumatologiske sygdomme

Mads Lamm Larsen; Anne Voss; Christoffer Tandrup Holst Nielsen; Ellen Margrethe Hauge; Mikkel Faurschou; Anne Troldborg

doi:10.61409/V06240429

Kimærisk antigenreceptor T-cellebehandling til refraktære systemiske autoimmune reumatologiske sygdomme

Translated title of the contribution: Chimeric antigen receptor T-cell therapy for refractory systemic autoimmune rheumatological diseases

Mads Lamm Larsen, Anne Voss, Christoffer Tandrup Holst Nielsen, Ellen Margrethe Hauge, Mikkel Faurschou, Anne Troldborg^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

Chimeric antigen receptor T-cell (CAR-T) therapy is emerging as a novel treatment for systemic autoimmune rheumatic diseases. To date, CAR-T therapy in rheumatology has been reported only in case studies and conference abstracts, but clinical trial results are forthcoming. Current evidence indicates a rapid and highly effective therapeutic response with a favourable side effect profile, suggesting that CD19 CAR-T therapy could be beneficially established for these conditions. Initially, CAR-T therapy appears relevant for a select group of severe, treatment-resistant rheumatic diseases.

Translated title of the contribution	Chimeric antigen receptor T-cell therapy for refractory systemic autoimmune rheumatological diseases
Original language	Danish
Article number	V06240429
Journal	Ugeskrift for Læger
Volume	187
Issue number	5
ISSN	0041-5782
DOIs	https://doi.org/10.61409/V06240429
Publication status	Published - 3. Mar 2025

Documents & Links

10.61409/V06240429Licence: CC BY-NC-ND

Open Access VersionFinal published version, 931 KBLicence: CC BY-NC-ND

Cite this

@article{a6ff4a9fafd54356827f6463e44d364f,

title = "Kim{\ae}risk antigenreceptor T-cellebehandling til refrakt{\ae}re systemiske autoimmune reumatologiske sygdomme",

abstract = "Chimeric antigen receptor T-cell (CAR-T) therapy is emerging as a novel treatment for systemic autoimmune rheumatic diseases. To date, CAR-T therapy in rheumatology has been reported only in case studies and conference abstracts, but clinical trial results are forthcoming. Current evidence indicates a rapid and highly effective therapeutic response with a favourable side effect profile, suggesting that CD19 CAR-T therapy could be beneficially established for these conditions. Initially, CAR-T therapy appears relevant for a select group of severe, treatment-resistant rheumatic diseases.",

keywords = "Antigens, CD19/immunology, Autoimmune Diseases/therapy, Humans, Immunotherapy, Adoptive/methods, Lupus Erythematosus, Systemic/therapy, Receptors, Antigen, T-Cell/therapeutic use, Receptors, Chimeric Antigen/immunology, Rheumatic Diseases/therapy, T-Lymphocytes/immunology",

author = "{Lamm Larsen}, Mads and Anne Voss and {Holst Nielsen}, {Christoffer Tandrup} and Hauge, {Ellen Margrethe} and Mikkel Faurschou and Anne Troldborg",

year = "2025",

month = mar,

day = "3",

doi = "10.61409/V06240429",

language = "Dansk",

volume = "187",

journal = "Ugeskrift for L{\ae}ger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "5",

}

TY - JOUR

T1 - Kimærisk antigenreceptor T-cellebehandling til refraktære systemiske autoimmune reumatologiske sygdomme

AU - Lamm Larsen, Mads

AU - Voss, Anne

AU - Holst Nielsen, Christoffer Tandrup

AU - Hauge, Ellen Margrethe

AU - Faurschou, Mikkel

AU - Troldborg, Anne

PY - 2025/3/3

Y1 - 2025/3/3

N2 - Chimeric antigen receptor T-cell (CAR-T) therapy is emerging as a novel treatment for systemic autoimmune rheumatic diseases. To date, CAR-T therapy in rheumatology has been reported only in case studies and conference abstracts, but clinical trial results are forthcoming. Current evidence indicates a rapid and highly effective therapeutic response with a favourable side effect profile, suggesting that CD19 CAR-T therapy could be beneficially established for these conditions. Initially, CAR-T therapy appears relevant for a select group of severe, treatment-resistant rheumatic diseases.

AB - Chimeric antigen receptor T-cell (CAR-T) therapy is emerging as a novel treatment for systemic autoimmune rheumatic diseases. To date, CAR-T therapy in rheumatology has been reported only in case studies and conference abstracts, but clinical trial results are forthcoming. Current evidence indicates a rapid and highly effective therapeutic response with a favourable side effect profile, suggesting that CD19 CAR-T therapy could be beneficially established for these conditions. Initially, CAR-T therapy appears relevant for a select group of severe, treatment-resistant rheumatic diseases.

KW - Antigens, CD19/immunology

KW - Autoimmune Diseases/therapy

KW - Humans

KW - Immunotherapy, Adoptive/methods

KW - Lupus Erythematosus, Systemic/therapy

KW - Receptors, Antigen, T-Cell/therapeutic use

KW - Receptors, Chimeric Antigen/immunology

KW - Rheumatic Diseases/therapy

KW - T-Lymphocytes/immunology

U2 - 10.61409/V06240429

DO - 10.61409/V06240429

M3 - Tidsskriftartikel

C2 - 39575908

SN - 0041-5782

VL - 187

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

IS - 5

M1 - V06240429

ER -

Kimærisk antigenreceptor T-cellebehandling til refraktære systemiske autoimmune reumatologiske sygdomme

Abstract

Documents & Links

Fingerprint

Cite this